How Much Do You Really Need Invested in Bristol Myers Squibb to Collect $10,000 a Year?
Collecting $10,000 a year from Bristol Myers Squibb sounds straightforward until you factor in a looming patent cliff that threatens the very earnings funding that payout. Here is what the math and the risk actually look like together.
The exercise is simple: how large a position in Bristol Myers Squibb (NYSE:BMY | BMY Price Prediction) do you need to throw off $10,000 a year in dividend income? Start with the income target and solve backward, using the live yield and the live payout. That is the only way the number means anything.
Bristol Myers Squibb is a global biopharmaceutical company that develops and sells prescription medicines across oncology, hematology, immunology and cardiovascular disease, with headline franchises including Eliquis, Opdivo, Reblozyl, Camzyos, Breyanzi, Opdualag and Cobenfy. It is a large-cap pharma with a market capitalization of roughly $130.0 billion and $49.19 billion in trailing revenue.
Live Math on BMY
The dividend inputs, straight off the tape:
- Forward annual dividend: $2.52 per share, paid as a $0.63 quarterly.
- Share price: $63.62 as of September 11, 2026.
- Dividend yield: 3.94%.
The share count needed for $10,000 in annual income equals the target divided by the per-share dividend ($10,000 / $2.52). The capital required equals that share count multiplied by the current price ($63.62). At the current 3.94% yield, the capital figure lands near a quarter of a million dollars, and the share count sits just under four thousand. Plug in the live quote before you size anything, because both variables move.
What This Snapshot Does and Does Not Tell You
The capital figure is a photograph at today’s price and today’s payout. It changes when either changes. Buy at a lower price and you need less money to reach $10,000. Buy at a higher price and you need more. A dividend increase lowers the bar over time. A cut raises it. BMY’s dividend history is one of the longer streaks in large-cap pharma: 17 consecutive annual increases and 94 consecutive years of dividend payments, with the most recent hike a 1.6% bump alongside the Q4 2025 earnings report.
Risk Income Articles Skip: Patent Cliffs
Ten thousand dollars a year from one pharmaceutical company is a large position facing one set of risks. The dominant one is structural. Pharmaceutical revenue runs on patents, and patents expire. When exclusivity ends on a major drug, generic and biosimilar competition can take a large share of that revenue in a hurry.
For BMY, the specific number to internalize is Eliquis, the company’s largest product at $4.14 billion in Q1 2026 revenue, up 16% year over year. Management still expects a $1.5 to $2 billion revenue step-down in 2027 tied to Eliquis pricing and European loss of exclusivity, with U.S. loss of exclusivity landing in April 2028. The Legacy Portfolio (Revlimid, Pomalyst, Sprycel, Abraxane) is already declining 12 to 16% on generic pressure. If the pipeline does not backfill on time, the earnings power that funds the payout narrows.
Balance Sheet Muscle and Growth Portfolio Momentum
BMY has real financial firepower. Management pointed to roughly $11.5 billion in cash and marketable securities at the end of Q2, $3.4 billion in quarterly operating cash flow, and $1.2 billion of additional debt paydown in the same quarter. The Growth Portfolio (Opdivo, Reblozyl, Camzyos, Breyanzi, Opdualag, Cobenfy) is now nearly 60% of total revenue and grew 14%. Management has flagged the potential for more than 10 new medicines by the end of the decade plus over 30 lifecycle management opportunities. The stock has also rerated: shares are up 40.25% over the past year and 21.94% year-to-date, with a forward P/E of 10.
What to Watch on the Income
- Pull the live yield and price before sizing. At $2.52 per share, a $63.62 price implies a very different share count than a $50 or $75 print.
- Track free cash flow coverage of the dividend each quarter. The commitment is only as durable as the cash generating it.
- Watch pipeline readouts that determine whether Eliquis revenue gets replaced, including Milvexian’s atrial fibrillation readout in Q1 2027, the mesignamide PDUFA on May 13, 2027, and Cobenfy ADEPT readouts starting early 2027.
The math is easy. The risk is the patent cliff. Size the position around both.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
